使用功能性 NK 细胞的过继免疫疗法取决于是否有足够数量的这些细胞。我们将脐带血 (UCB)-CD34 HSC 扩增 2 周，然后将其分化为 NK 细胞，并将其功能与外周血 (PB) NK 细胞进行比较。我们评估了与 K562 细胞系共培养后两组的 NKG2D、NKG2A、NKp30、NKp44、NKp46 以及 CD107a、CD57、CD69、FasL、PD-1 和 IFN-γ 的表达水平。我们发现 UCB-CD34 衍生的 NK 细胞比 PB NK 细胞表达显着更多的 NKG2D、NKp44 和 NKp46 受体。 PB NK 细胞表达的 NKG2A 和 CD57 明显高于 UCB-CD34 衍生的 NK 细胞。此外，UCB-CD34衍生的NK细胞比PB NK细胞更显着地表达CD107a。根据我们的研究结果，UCB-CD34 细胞可能是具有强大细胞毒功能的潜在有利来源，可产生用于过继性癌症免疫治疗的同种异体 NK 细胞。© 2024 作者。

Adoptive immunotherapies that use functional NK cells depend on the availability of sufficient numbers of these cells. We expanded umbilical cord blood (UCB)-CD34+ HSCs for 2 weeks and then differentiated them into NK cells and compared their function to peripheral blood (PB) NK cells. We assessed NKG2D, NKG2A, NKp30, NKp44, NKp46, and the expression of CD107a, CD57, CD69, FasL, PD-1, and IFN-γ level in two groups after co-culture with K562 cell line. We found that UCB-CD34+-derived NK cells express significantly more NKG2D, NKp44, and NKp46 receptors than PB NK cells. PB NK cells expressed significantly higher NKG2A and CD57 than UCB-CD34+-derived NK cells. In addition, UCB-CD34+-derived NK cells significantly expressed CD107a more than PB NK cells. Based on our findings, UCB-CD34+ cells can be a potentially advantageous source with strong cytotoxic function to produce allogeneic NK cells for adoptive cancer immunotherapy.© 2024 The Author(s).